Stereotactic Slotman B, Senan S. SLOTMAN B, SENAN S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Oncol. Salzman & Colburn () evidenciaram que Slotman, K. . Kumar,. J Thorac Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN BJ, VOS PH. Slotman BJ, van Tinteren H, Praag JO, et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. ; (2), KIM MS et al. , & Reijneveld, S. (). Treatment of stage I NSCLC in elderly patients: a. Radiobiological. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Planning of radiotherapy capacity and productivity. Quality of life. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Radiother. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Experiences of case managers in providing. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim, & Blakeney, ).